Why Buy Domino’s Pizza Stock?
When you think of growth stocks, you probably imagine technology…
Sell
11
NRIX Quote, Financials, Valuation and Earnings
Last price:
$19.68
Seasonality move
:
-8.92%
Day range:
$19.42 - $20.20
52-week range:
$7.65 - $29.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.37x
P/B ratio:
3.70x
Volume:
659.1K
Avg. volume:
861.8K
1-year change:
104.46%
Market cap:
$1.4B
Revenue:
$77M
EPS (TTM):
-$2.91
Analysts' Opinion
-
Consensus RatingNurix Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.65, Nurix Therapeutics has an estimated upside of 62.06% from its current price of $19.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $19.71.
Fair Value
-
According to the consensus of 10 analysts, Nurix Therapeutics has 62.06% upside to fair value with a price target of $31.65 per share.
NRIX vs. S&P 500
-
Over the past 5 trading days, Nurix Therapeutics has underperformed the S&P 500 by -0.63% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Nurix Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Nurix Therapeutics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Nurix Therapeutics reported revenues of $12.6M.
Earnings Growth
-
Nurix Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Nurix Therapeutics reported earnings per share of -$0.67.
Enterprise value:
948.1M
EV / Invested capital:
--
Price / LTM sales:
21.37x
EV / EBIT:
--
EV / Revenue:
16.80x
PEG ratio (5yr expected):
-1.16x
EV / Free cash flow:
-8.87x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-44.22%
Net Income Margin (TTM):
-313.65%
Return On Equity:
-65.52%
Return On Invested Capital:
-65.52%
Operating Margin:
-433.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2023-08-31 | 2024-08-31 | |
| Income Statement | ||||||
| Revenue | $39.2M | $68.6M | $56.4M | $18.5M | $12.6M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$173.1M | -$158.4M | -$193.7M | -$40M | -$54.6M | |
| EBITDA | -$163.7M | -$145.5M | -$177.8M | -$36.6M | -$50.5M | |
| Diluted EPS | -$3.71 | -$2.75 | -$2.91 | -$0.68 | -$0.67 | |
| Period Ending | 2020-08-31 | 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $364.1M | $358.4M | $354.9M | $267.9M | $456M | |
| Total Assets | $411.9M | $493.1M | $459.3M | $308.2M | $513.6M | |
| Current Liabilities | $41M | $50.7M | $67.5M | $61.5M | $86.3M | |
| Total Liabilities | $104.3M | $117.9M | $116.8M | $74.4M | $136.7M | |
| Total Equity | $307.6M | $375.2M | $342.5M | $233.8M | $376.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2023-08-31 | 2024-08-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$152.8M | -$146M | -$97.1M | -$41.1M | -$42.2M | |
| Cash From Investing | -$64.3M | $137.7M | -$131.3M | $22.8M | -$21.3M | |
| Cash From Financing | $117.8M | $3.1M | $285.2M | $1.7M | $45.8M | |
| Free Cash Flow | -$163.3M | -$154.4M | -$106.9M | -$43.6M | -$44.5M | |
NRIX
Sector
Market Cap
$1.4B
$49.2M
Price % of 52-Week High
66.68%
48.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
104.46%
-30.94%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$19.41
200-day SMA
Sell
Level
$20.10
Bollinger Bands (100)
Sell
Level
20.97 - 25.39
Chaikin Money Flow
Sell
Level
-973.2K
20-day SMA
Sell
Level
$20.18
Relative Strength Index (RSI14)
Sell
Level
43.05
ADX Line
Buy
Level
17.99
Williams %R
Neutral
Level
-58.3333
50-day SMA
Sell
Level
$22.61
MACD (12, 26)
Sell
Level
-0.87
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
13.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.493)
Sell
CA Score
(Annual)
Level (-1.4961)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.4468)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Stock Forecast FAQ
In the current month, NRIX has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NRIX average analyst price target in the past 3 months is $31.65.
-
Where Will Nurix Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Nurix Therapeutics share price will rise to $31.65 per share over the next 12 months.
-
What Do Analysts Say About Nurix Therapeutics?
Analysts are divided on their view about Nurix Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Nurix Therapeutics is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Nurix Therapeutics's Price Target?
The price target for Nurix Therapeutics over the next 1-year time period is forecast to be $31.65 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NRIX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Nurix Therapeutics is a Buy. 9 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NRIX?
You can purchase shares of Nurix Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Nurix Therapeutics shares.
-
What Is The Nurix Therapeutics Share Price Today?
Nurix Therapeutics was last trading at $19.68 per share. This represents the most recent stock quote for Nurix Therapeutics. Yesterday, Nurix Therapeutics closed at $19.71 per share.
-
How To Buy Nurix Therapeutics Stock Online?
In order to purchase Nurix Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Companies Are In The VanEck Semiconductor ETF?
There’s a lot to love about the VanEck Semiconductor ETF,…
How High Can Palantir Stock Go?
Palantir Technologies (NASDAQ:PLTR) has been one of the undisputed victors…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 121x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
39
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
